{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:19Z","timestamp":1761901819717,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZZ1603","01ZZ1804"],"award-info":[{"award-number":["01ZZ1603","01ZZ1804"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.msard.2021.103075","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:27:06Z","timestamp":1623072426000},"page":"103075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets \u2013 expert opinion on issues in clinical practice"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-5398","authenticated-orcid":false,"given":"Martin","family":"Stangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veit","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birte","family":"Elias-Hamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Havla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-6692","authenticated-orcid":false,"given":"Christoph","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-3762","authenticated-orcid":false,"given":"Daniela","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103075_bib0001","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1352458517726380","article-title":"Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis","volume":"24","author":"Afolabi","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103075_bib0002","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103075_bib0003","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.msard.2021.103075_bib0004","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), 2020","first-page":"P1066","article-title":"Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets","author":"Brochet","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0005","unstructured":"Center of Evidence Based Medicine, Oxford. Essential Evicence Plus, Levels of Evidence. https:\/\/www.essentialevidenceplus.com\/product\/ebm_loe.cfm?show=oxford (accessed 16 March 2021)."},{"key":"10.1016\/j.msard.2021.103075_bib0007","unstructured":"Clinical Competence Network Multiple Sclerosis (Klinisches Kompetenznetzwerk Multiple Sklerose, Germany), Quality Handbook 2020. https:\/\/www.kompetenznetz-multiplesklerose.de\/wp-content\/uploads\/2020\/03\/KKNMS_Qualit%C3%A4tshandbuch-MSNMOSD_202001_webfrei-1.pdf (accessed 16 March 2021)."},{"key":"10.1016\/j.msard.2021.103075_bib0049","unstructured":"Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials (PREMIERE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01013350 (accessed 4 February 2021)."},{"key":"10.1016\/j.msard.2021.103075_bib0008","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103075_bib0009","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting","first-page":"P1390","article-title":"Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data","author":"Cook","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Dis."},{"key":"10.1016\/j.msard.2021.103075_bib0011","doi-asserted-by":"crossref","unstructured":"Datta, P., Ciplea, A.I., Rewers-Felkins, K., Baker, T., Gold, R., Hale, T.W., Hellwig, K., 2020. Cladribine transfer into human milk: A case report. Multiple Sclerosis 1352458520912173. Advance online publication. https:\/\/doi.org\/10.1177\/1352458520912173.","DOI":"10.1177\/1352458520912173"},{"key":"10.1016\/j.msard.2021.103075_bib0012","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)","first-page":"P0382","article-title":"Reduction in CUA MRI Lesions in the First 6 Months of Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Study","author":"De Stefano","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0013","unstructured":"European Medicines Agency. Assessment report, cladribine tablets (Mavenclad), June 2017, p 103, https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mavenclad-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.msard.2021.103075_bib0014","unstructured":"European Medicines Agency. Summaries of product characteristics of licensed MS drugs, (accessed 16 March 2020)."},{"key":"10.1016\/j.msard.2021.103075_bib0015","unstructured":"European Medicines Agency, Shingrix (recombinant adjuvanted herpes zoster vaccine), summary of product Characteristics. August 2020a."},{"key":"10.1016\/j.msard.2021.103075_bib0016","unstructured":"European Medicines Agency. Mavenclad (cladribine tablets), summary of product characteristics February 2021."},{"key":"10.1016\/j.msard.2021.103075_bib0017","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=25028 (accessed 16 March 2021)."},{"key":"10.1016\/j.msard.2021.103075_bib0018","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study","volume":"3","author":"Freedman","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103075_bib0019","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, 2017","first-page":"P1878","article-title":"Pregnancy outcomes during the clinical development programme of cladribine in multiple sclerosis (MS): an integrated analysis of safety for all exposed patients","author":"Galazka","year":"2017"},{"key":"10.1016\/j.msard.2021.103075_bib0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.msard.2021.103075_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103075_bib0022","series-title":"Presented at Congress of the European Academy of Neurology (EAN)","first-page":"O747","article-title":"Pooled analysis of the efficacy of cladribine tablets 3.5 mg\/kg in patients with EDSS\u2009\u2265\u20093.5 or\u2009\u2264\u20093.0 at baseline in the CLARITY and ONWARD studies","author":"Giovannoni","year":"2018"},{"key":"10.1016\/j.msard.2021.103075_bib0023","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103075_bib0024","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, 2019","first-page":"EP1573","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the CLARITY and CLARITY extension studies","author":"Giovannoni","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0025","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), 2020","first-page":"P0415","article-title":"Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections","author":"Giovannoni","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0026","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), 2020","first-page":"LB1229","article-title":"CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients Receiving Cladribine Tablets - Interim Data with 8\u201314 Years\u2019 Follow-up","author":"Giovannoni","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0027","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), 2020","first-page":"P0202","article-title":"Durable Efficacy of Cladribine Tablets: Cumulative Relapse Incidence over 5 years in CLARITY and CLARITY Extension","author":"Giovannoni","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0028","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103075_bib0029","first-page":"27","article-title":"Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms","volume":"22-S2","author":"Kalatskaya","year":"2020","journal-title":"Int J MS Care"},{"key":"10.1016\/j.msard.2021.103075_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102242","article-title":"The transitional phase of multiple sclerosis: characterization and conceptual framework","volume":"44","author":"Kleiter","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103075_bib0031","article-title":"Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther","volume":"12","author":"Klotz","year":"2019","journal-title":"Adv. Neurol. Dis."},{"key":"10.1016\/j.msard.2021.103075_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2021.103075_bib0032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103075_bib0034","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103075_bib0035","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103075_bib0036","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, 2019","first-page":"EP1593","article-title":"Year 1 performance of adveva\u00ae, a patient support programme (PSP) for patients taking Mavenclad\u00ae (cladribine tablets) for highly active relapsing remitting multiple sclerosis (RRMS) in United Kingdom (UK)","author":"Lyons","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0037","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion","volume":"21","author":"Meuth","year":"2020","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.msard.2021.103075_bib0038","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, 2019","first-page":"EP1577","article-title":"Cladribine tablets: observational evaluation of effectiveness, safety, and patient reported outcomes in suboptimally controlled patients previously taking injectable disease-modifying drugs for relapsing forms of multiple sclerosis (CLICK-MS)","author":"Miravalle","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0039","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: The ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103075_bib0041","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2018.12.014","article-title":"Multiple sclerosis and cancer incidence: A Danish nationwide cohort study","volume":"28","author":"N\u00f8rgard","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103075_bib0040","unstructured":"National Cancer Institute. Surveillance, Epidemiology an End Results Program. https:\/\/seer.cancer.gov (accessed 9 November 2020)."},{"key":"10.1016\/j.msard.2021.103075_bib0042","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103075_bib0043","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther","volume":"13","author":"Patti","year":"2020","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103075_bib0044","series-title":"Presented at MS Virtual Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), 2020","first-page":"P0849","article-title":"CLADQoL (CLADribine Tablets \u2013 evaluation of Quality of Life) study: evaluating Qol 12 months after treatment initiation with cladribine tablets","author":"Penner","year":"2020"},{"key":"10.1016\/j.msard.2021.103075_bib0047","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103075_bib0046","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2021.103075_bib0048","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"198","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103075_bib0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology,"},{"key":"10.1016\/j.msard.2021.103075_bib0051","series-title":"Presented at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting, 2021","first-page":"P059","article-title":"Analysis of Influenza and Varicella Zoster Virus Vaccine Antibody Titers in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets","author":"Roy","year":"2021"},{"key":"10.1016\/j.msard.2021.103075_bib0052","series-title":"Presented at Annual Meeting of the American Academy of Neurology, 2009","article-title":"Cellular expression of genes involved in cladribine metabolism","author":"Salvat","year":"2009"},{"key":"10.1016\/j.msard.2021.103075_bib0053","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Dis."},{"key":"10.1016\/j.msard.2021.103075_bib0054","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"1","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol., 23 Suppl."},{"key":"10.1016\/j.msard.2021.103075_bib0055","series-title":"on behalf of the CLARITY Study GroupPresented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting,","first-page":"P817","article-title":"Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled clarity study","author":"Vermersch","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0056","series-title":"Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting","first-page":"P385","article-title":"Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with Cladribine tablets: an analysis of the CLARITY study","author":"Vermersch","year":"2019"},{"key":"10.1016\/j.msard.2021.103075_bib0057","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clinthera.2018.12.015","article-title":"Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis","volume":"41","author":"Vermersch","year":"2019","journal-title":"Clinical therapeutics"},{"key":"10.1016\/j.msard.2021.103075_bib0058","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fimmu.2016.00314","article-title":"Adenosine Deaminase Deficiency \u2013 More Than Just an Immunodeficiency","volume":"7","author":"Whitmore","year":"2016","journal-title":"Front. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2021.103075_bib0059","first-page":"482","article-title":"Preservation of Relapse-free Status in Year 2 of Treatment with Cladribine Tablets by Relapse-free Status in Year 1","volume":"27","author":"Yamout","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103075_bib0060","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:43Z","timestamp":1761901123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821003424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":58,"alternative-id":["S2211034821003424"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103075","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets \u2013 expert opinion on issues in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103075"}}